Recombinant human serum amyloid P

Table of contents


Please note that this product was withdrawn from the Community Register of designated Orphan Medicinal Products in March 2014 on request of the Sponsor.

On 9 October 2009, orphan designation (EU/3/09/674) was granted by the European Commission to RegPak BioPharma Consulting, The Netherlands, for recombinant human serum amyloid P for the prevention of scarring post glaucoma filtration surgery.

The sponsorship was transferred to Appletree Europe S.à.r.l., Luxembourg, in August 2010.

For a list of the administrative updates to this public summary of opinion please refer to the PDF document below.

Key facts

Active substance
Recombinant human serum amyloid P
Intented use
Prevention of scarring post glaucoma filtration surgery
Date of designation
Orphan designation status
EU designation number

Sponsor's contact details

Appletree Europe S.à.r.l.
46A, Avenue J.F. Kennedy
L-1855 Luxembourg
Telephone: +352 2748 8088
Telefax: +352 2748 8479

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

  • Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.

  • European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.

How useful was this page?

Add your rating